Welcome to our dedicated page for Arvinas SEC filings (Ticker: ARVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arvinas, Inc. filings document regulatory, clinical, financial, and governance disclosures for a biotechnology company built around PROTAC targeted protein degradation. Recent Form 8-K reports cover FDA approval of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, clinical data for ARV-102 in Parkinson’s disease, preclinical data for ARV-806 as a KRAS G12D degrader, and patient-reported outcomes for vepdegestrant.
The company’s filings also record quarterly and annual financial results, corporate updates, executive and board leadership changes, and proxy matters. Its definitive proxy statement addresses board elections, executive compensation, equity awards, shareholder voting items, and other governance information for Arvinas as a Nasdaq-listed operating company.
Arvinas, Inc. notice under Rule 144 reports the settlement and intended sale of 11,312 shares of Common Stock via Morgan Stanley Smith Barney on 05/11/2026, described as the settlement of vested restricted stock units. The filing also records prior dispositions by Noah Berkowitz of 5,685 shares on 02/13/2026 for $67,594.65 and 6,435 shares on 03/18/2026 for $71,431.07.
Arvinas, Inc. submitted a Form 144 notifying the sale/settlement of 9,834 shares of Common Stock tied to the settlement of vested restricted stock units on 05/11/2026. The filing also reports prior dispositions by Randy Teel of 4,403 shares on 02/13/2026 and 4,786 shares on 02/23/2026 with reported values.
Arvinas, Inc. announced that the U.S. Food and Drug Administration has approved VEPPANU (vepdegestrant) to treat adults with ER-positive/HER2-negative, ESR1‑mutated advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine therapy, based on an FDA‑authorized test. VEPPANU is described as the first-and-only FDA‑approved PROTAC protein degrader, marking Arvinas’ first approved medicine and the first PROTAC therapy to reach the market. FDA approval came ahead of the June 5, 2026 PDUFA date. In the Phase 3 VERITAC‑2 trial, VEPPANU reduced the risk of disease progression or death by 43% versus fulvestrant, with median progression‑free survival of 5.0 months compared to 2.1 months. Under its collaboration with Pfizer, Arvinas will receive a $50.0 million development milestone payment tied to this approval, which will be offset by amounts owed to Yale University under a license agreement. Arvinas and Pfizer plan to select a third‑party partner to commercialize VEPPANU.
Arvinas, Inc. is holding its 2026 Annual Meeting of Stockholders as a virtual-only audio webcast on June 24, 2026 at 8:00 a.m. Eastern Time.
Stockholders of record at the close of business on April 27, 2026, holding 64,517,472 shares of common stock, will vote on electing two Class II directors, an advisory say‑on‑pay resolution on executive compensation, and ratification of Deloitte & Touche LLP as independent auditor for 2026. The board recommends voting FOR all three proposals and explains detailed voting procedures for stockholders of record and those holding shares in street name.
Vanguard Portfolio Management reports beneficial ownership of 3,917,671 shares of Arvinas Inc. This holding represents 6.12% of Arvinas' common stock and is reported on a Schedule 13G. Vanguard Portfolio Management discloses sole dispositive power over 3,917,671 shares and sole voting power for 28,043 shares.
The filing lists CUSIP 04335A105 and is signed by Ashley Grim on 04/28/2026.
The Vanguard Group filed Amendment No. 5 on a Schedule 13G/A reporting beneficial ownership of 0 shares of Arvinas Inc common stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026
The filing cites SEC Release No. 34-39538 and states certain Vanguard subsidiaries will report beneficial ownership separately following the realignment. The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Arvinas, Inc. Chief Medical Officer Noah Berkowitz reported an automatic share disposition related to tax withholding. On March 18, he sold 6,435 shares of common stock at an average price of $11.1004 per share. According to the footnote, this sale was made automatically by the company to cover tax withholding obligations tied to the vesting and settlement of 25% of his restricted stock units granted on March 18, 2024, and did not represent a discretionary trade. After this transaction, he directly held 202,503 shares of Arvinas common stock.
Arvinas, Inc. reported positive Phase 1 data for ARV-102, an investigational oral PROTAC degrader of LRRK2 in patients with Parkinson’s disease. Multiple daily doses of 20 mg, 40 mg, and 80 mg for 28 days were well tolerated, with only mild adverse events, no serious adverse events, no discontinuations, and no deaths, and no significant changes in lung function.
ARV-102 showed brain penetration with cerebrospinal fluid exposure increasing in a dose-dependent manner and a mean plasma half-life of 68 hours. It achieved approximately 50% or greater LRRK2 reduction in cerebrospinal fluid at all doses by day 14, maintained through day 28, and reduced endolysosomal and neuroinflammatory biomarkers such as CD68 and GPNMB.
Based on these results, Arvinas plans to continue developing ARV-102 in neurodegenerative diseases linked to LRRK2 and endolysosomal dysfunction and, pending regulatory feedback, intends to start a Phase 1b trial in progressive supranuclear palsy in the second quarter of 2026, with potential initiation of a registrational trial in late 2026.
Arvinas, Inc. submitted a Rule 144 notice reporting the settlement of 6,022 vested restricted stock units on 03/18/2026 through Morgan Stanley Smith Barney LLC and a prior sale of 5,685 shares by Noah Berkowitz on 02/13/2026 for $67,594.65.
The filing lists the securities as Common stock to be sold via settlement of vested RSUs; the sale by Berkowitz is reported in the "Securities Sold During The Past 3 Months" section.